Shares of TG Therapeutics experienced a significant increase on Wednesday following the announcement that their under-the-skin injection of Briumvi demonstrated safety comparable to the intravenous administration. This positive news resulted in an early buy signal for the biotech company, contributing to the bullish jump in the stock. The company's stock price surged by (mention percentage increase) as investors reacted to the encouraging development. The switch to a different route of administration for Briumvi could potentially lead to increased interest from investors and further growth opportunities for TG Therapeutics.